Working… Menu
Trial record 9 of 41 for:    Interventional Studies | Osteogenesis Imperfecta

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03064074
Recruitment Status : Recruiting
First Posted : February 24, 2017
Last Update Posted : April 5, 2021
Genzyme, a Sanofi Company
Oregon Health and Science University
Information provided by (Responsible Party):
Brendan Lee, Baylor College of Medicine

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2023